Validating new biomarkers for tumor diagnosis and therapy is crucial, as current targets such as EGFR, HER2, and VEGFR2 are insufficient for treating various solid tumors and dealing with emerging drug resistance. This evidence concerns the gene ERBB2 and neoplasm.